Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...

We recently compiled a list of the 12 Best Low Risk High Growth Stocks to Invest In. In this article, we are going to take a ...

Q4 2024 Management View CEO Kyle Gano highlighted Neurocrine's transformation into a fully integrated biopharmaceutical company. He emphasized the strong performance of INGREZZA, which is poised for ...

Neurocrine (NBIX) delivered earnings and revenue surprises of -35.90% and 0.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences Inc (NBIX) reported earnings for fourth quarter that decreased from the same period last year and missed the ...

Neurocrine Biosciences missed estimated earnings by -1.0%, reporting an EPS of $1.69 versus an estimate of $1.71. Revenue was up $112.50 million from the same period last year. During the previous ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Neurocrine Biosciences Inc. (NBIX) on Thursday reported fourth-quarter earnings of $103.1 million. The San Diego-based company said it had profit of $1 per share.

Tokio Marine Asset Management Co. Ltd. cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.8% ...

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $169.43, a high estimate of $190.00, and a low estimate of $148.00. Observing a ...